Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm
Mandate

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

June 11, 2021 Capital Markets and Public M&A Corporate Tax M&A

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market. The prospectus was published on 8 June 2021 and the trading on Nasdaq Stockholm commenced on 11 June 2021.

Sdiptech is a technology group that acquires and develops market-leading niche operations that contribute to creating more sustainable, efficient and safe societies. Sdiptech has approximately SEK 2,000 million in sales and is based in Stockholm.

Vinge’s team has primarily consisted of Dain Hård Nevonen, William Kåge, Anders Sundin Lundberg and Benjamin Vafaeian (Capital Markets and Public M&A), Jesper Lindvall and Eléonore Friberg (M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026